Cencora’s specialty-services transition and durable cash generation make the post-earnings selloff an attractive long-term value opportunity despite near-term revenue pressure.
Overview
Cencora, formerly AmerisourceBergen, is a critical pharmaceutical infrastructure provider distributing branded, generic and specialty medicines to pharmacies, hospitals, providers and manufacturers. It generated $321.33 billion of fiscal 2025 revenue, with U.S. Healthcare Solutions contributing $284.96 billion and 77.74% of adjusted operating income, while International Healthcare Solutions contributed $28.33 billion and 13.92% of adjusted operating income. **Its competitive position is unusually defensive:** Cencora, McKesson and Cardinal Health control more than 90% of U.S. drug distribution, supported by scale, purchasing power, integrated technology and high switching costs. Fiscal Q2 2026 revenue rose 3.8% to $78.36 billion but missed consensus, triggering a 17.6% one-day selloff. Management cut FY2026 revenue growth guidance to 4%–6%, yet raised adjusted operating-income growth guidance to 12%–14% and adjusted diluted EPS guidance to $17.65–$17.90. The stock trades at approximately 19.5x forward P/E versus a 22.4x healthcare-sector average. Near-term catalysts include Q3 earnings on August 5, 2026, resumed buybacks, RCA and OneOncology integration, and specialty-market growth. **The report views the selloff as an attractive long-term entry point rather than a broken thesis.**